Period,symbol,NAV,sharesOutstanding,researchDevelopment,effectOfAccountingCharges,incomeBeforeTax,minorityInterest,netIncome,sellingGeneralAdministrative,grossProfit,ebit,operatingIncome,otherOperatingExpenses,interestExpense,extraordinaryItems,nonRecurring,otherItems,incomeTaxExpense,totalRevenue,totalOperatingExpenses,costOfRevenue,totalOtherIncomeExpenseNet,discontinuedOperations,netIncomeFromContinuingOps,netIncomeApplicableToCommonShares,capitalSurplus,totalLiab,totalStockholderEquity,otherCurrentLiab,totalAssets,commonStock,retainedEarnings,treasuryStock,otherAssets,cash,totalCurrentLiabilities,otherStockholderEquity,propertyPlantEquipment,totalCurrentAssets,longTermInvestments,shortTermInvestments,accountsPayable,netReceivables,investments,changeToLiabilities,totalCashflowsFromInvestingActivities,totalCashFromFinancingActivities,changeToOperatingActivities,issuanceOfStock,changeInCash,totalCashFromOperatingActivities,depreciation,changeToNetincome,capitalExpenditures,WC,language,region,quoteType,triggerable,quoteSourceName,regularMarketChangePercent,regularMarketDayRange,regularMarketPreviousClose,bid,ask,bidSize,askSize,messageBoardId,fullExchangeName,longName,financialCurrency,averageDailyVolume3Month,averageDailyVolume10Day,fiftyTwoWeekLowChange,fiftyTwoWeekLowChangePercent,fiftyTwoWeekRange,fiftyTwoWeekHighChange,fiftyTwoWeekHighChangePercent,fiftyTwoWeekLow,fiftyTwoWeekHigh,earningsTimestamp,earningsTimestampStart,earningsTimestampEnd,epsTrailingTwelveMonths,epsForward,currency,priceHint,epsCurrentYear,priceEpsCurrentYear,bookValue,fiftyDayAverage,fiftyDayAverageChange,fiftyDayAverageChangePercent,twoHundredDayAverage,twoHundredDayAverageChange,twoHundredDayAverageChangePercent,marketCap,forwardPE,priceToBook,sourceInterval,exchangeTimezoneName,exchangeTimezoneShortName,gmtOffSetMilliseconds,exchange,exchangeDataDelayedBy,esgPopulated,tradeable,regularMarketPrice,regularMarketTime,regularMarketChange,regularMarketOpen,regularMarketDayHigh,regularMarketDayLow,regularMarketVolume,shortName,market,marketState,Beta (5Y Monthly),52-Week Change 3,S&P500 52-Week Change 3,52 Week High 3,52 Week Low 3,50-Day Moving Average 3,200-Day Moving Average 3,Avg Vol (3 month) 3,Avg Vol (10 day) 3,Shares Outstanding 5,Implied Shares Outstanding 6,Float,% Held by Insiders 1,% Held by Institutions 1,"Shares Short (May 27, 2021) 4","Short Ratio (May 27, 2021) 4","Short % of Float (May 27, 2021) 4","Short % of Shares Outstanding (May 27, 2021) 4","Shares Short (prior month Apr 29, 2021) 4",Forward Annual Dividend Rate 4,Forward Annual Dividend Yield 4,Trailing Annual Dividend Rate 3,Trailing Annual Dividend Yield 3,5 Year Average Dividend Yield 4,Payout Ratio 4,Dividend Date 3,Ex-Dividend Date 4,Last Split Factor 2,Last Split Date 3,Fiscal Year Ends,Most Recent Quarter (mrq),Profit Margin,Operating Margin (ttm),Return on Assets (ttm),Return on Equity (ttm),Revenue (ttm),Revenue Per Share (ttm),Quarterly Revenue Growth (yoy),Gross Profit (ttm),EBITDA,Net Income Avi to Common (ttm),Diluted EPS (ttm),Quarterly Earnings Growth (yoy),Total Cash (mrq),Total Cash Per Share (mrq),Total Debt (mrq),Total Debt/Equity (mrq),Current Ratio (mrq),Book Value Per Share (mrq),Operating Cash Flow (ttm),Levered Free Cash Flow (ttm),index,zip,sector,fullTimeEmployees,compensationRisk,auditRisk,longBusinessSummary,city,phone,state,shareHolderRightsRisk,compensationAsOfEpochDate,governanceEpochDate,boardRisk,country,website,maxAge,overallRisk,address1,fax,industry
t0,JNCE,279454000.0,51208400,9829000,,-26534000,,-26535000,8992000,-7762000,-26583000,-26583000,,,,,,1000,1539000,28122000,9301000,49000,,-26535000,-26535000,456964000.0,25699000.0,279454000.0,446000.0,305153000.0,51000.0,-177536000.0,-25000.0,3477000.0,196273000.0,12925000.0,-25000.0,20855000.0,267013000.0,13808000.0,61205000.0,1631000.0,,-9465000,-2057000,-9623000,91955000,-8709000,91955000,48780000,-33552000,785000,2964000,-158000,254088000.0,en-US,US,EQUITY,True,Delayed Quote,5.7877836,6.23 - 6.6,6.22,0.0,0.0,18,8,finmb_228489698,NasdaqGS,"Jounce Therapeutics, Inc.",USD,479864,512385,1.5499997,0.30815104,5.03 - 14.84,-8.26,-0.5566038,5.03,14.84,1620131400,1620131400,1620131400,-1.146,-2.02,USD,2,-1.39,-4.733813,5.458,5.5034285,1.0765715,0.19561833,8.193189,-1.6131887,-0.19689389,336951264,-3.2574258,1.2055697,15,America/New_York,EDT,-14400000,NMS,0,False,False,6.58,1630526403,0.36000013,6.24,6.6,6.23,317700,"Jounce Therapeutics, Inc.",us_market,PRE,1.12,,,14.84,5.03,5.5,8.19,479.86k,512.38k,51.21M,,30.39M,18.27%,71.69%,1.91M,6.61,5.28%,3.72%,1.97M,,,,,,0.00%,,,,,"Dec 30, 2020","Mar 30, 2021",-68.78%,-69.69%,-11.40%,-20.34%,63.88M,1.66,,25.35M,-41.27M,-43.93M,-1.15,,257.48M,5.03,16.15M,5.78,20.66,5.46,-37.79M,-20.7M,Value,02139,Healthcare,128,6,3,"Jounce Therapeutics, Inc., a clinical-stage immunotherapy company, develops therapies for the treatment of cancer. The company develops vopratelimab, a clinical-stage monoclonal antibody, which is in Phase II clinical trial that binds to and activates the Inducible T cell CO-Stimulator, a protein on the surface of T cells found in various solid tumors. It is also developing JTX-4014, an anti-PD-1 antibody for combination therapy; JTX-8064, an antibody that binds to leukocyte immunoglobulin like receptor B2, which is a cell surface receptor expressed on macrophages; and JTX-1811, an anti-CCR8 monoclonal antibody designed to selectively deplete intra-tumoral T regulatory cells in the tumor microenvironment. Jounce Therapeutics, Inc. was incorporated in 2012 and is headquartered in Cambridge, Massachusetts.",Cambridge,857 259 3840,MA,8,1609372800,1622505600,7,United States,http://jouncetx.com,86400,7,780 Memorial Drive,888 459 2940,Biotechnology
t-1,JNCE,211294000.0,51208400,7696000,,35472000,,35472000,12421000,55538000,35421000,35421000,,,,,,0,62339000,26918000,6801000,51000,,35472000,35472000,362270000.0,32942000.0,211294000.0,1973000.0,244236000.0,42000.0,-151001000.0,-17000.0,3943000.0,147493000.0,19324000.0,-17000.0,22192000.0,211391000.0,6710000.0,58985000.0,2036000.0,100000.0,-27692000,1224000,-27731000,68781000,-321000,68781000,80390000,39340000,800000,2165000,-39000,192067000.0,en-US,US,EQUITY,True,Delayed Quote,5.7877836,6.23 - 6.6,6.22,0.0,0.0,18,8,finmb_228489698,NasdaqGS,"Jounce Therapeutics, Inc.",USD,479864,512385,1.5499997,0.30815104,5.03 - 14.84,-8.26,-0.5566038,5.03,14.84,1620131400,1620131400,1620131400,-1.146,-2.02,USD,2,-1.39,-4.733813,5.458,5.5034285,1.0765715,0.19561833,8.193189,-1.6131887,-0.19689389,336951264,-3.2574258,1.2055697,15,America/New_York,EDT,-14400000,NMS,0,False,False,6.58,1630526403,0.36000013,6.24,6.6,6.23,317700,"Jounce Therapeutics, Inc.",us_market,PRE,1.12,,,14.84,5.03,5.5,8.19,479.86k,512.38k,51.21M,,30.39M,18.27%,71.69%,1.91M,6.61,5.28%,3.72%,1.97M,,,,,,0.00%,,,,,"Dec 30, 2020","Mar 30, 2021",-68.78%,-69.69%,-11.40%,-20.34%,63.88M,1.66,,25.35M,-41.27M,-43.93M,-1.15,,257.48M,5.03,16.15M,5.78,20.66,5.46,-37.79M,-20.7M,Value,02139,Healthcare,128,6,3,"Jounce Therapeutics, Inc., a clinical-stage immunotherapy company, develops therapies for the treatment of cancer. The company develops vopratelimab, a clinical-stage monoclonal antibody, which is in Phase II clinical trial that binds to and activates the Inducible T cell CO-Stimulator, a protein on the surface of T cells found in various solid tumors. It is also developing JTX-4014, an anti-PD-1 antibody for combination therapy; JTX-8064, an antibody that binds to leukocyte immunoglobulin like receptor B2, which is a cell surface receptor expressed on macrophages; and JTX-1811, an anti-CCR8 monoclonal antibody designed to selectively deplete intra-tumoral T regulatory cells in the tumor microenvironment. Jounce Therapeutics, Inc. was incorporated in 2012 and is headquartered in Cambridge, Massachusetts.",Cambridge,857 259 3840,MA,8,1609372800,1622505600,7,United States,http://jouncetx.com,86400,7,780 Memorial Drive,888 459 2940,Biotechnology
t-2,JNCE,105087000.0,51208400,9013000,,-24901000,,-24903000,7102000,-8989000,-25104000,-25104000,,,,,,2000,0,25104000,8989000,203000,,-24903000,-24903000,291481000.0,30746000.0,105087000.0,74000.0,135833000.0,34000.0,-186473000.0,45000.0,3678000.0,67103000.0,16280000.0,45000.0,23664000.0,107457000.0,1034000.0,37144000.0,2707000.0,,14449000,-330000,14444000,348000,-216000,348000,-7360000,-22152000,806000,2491000,-5000,91177000.0,en-US,US,EQUITY,True,Delayed Quote,5.7877836,6.23 - 6.6,6.22,0.0,0.0,18,8,finmb_228489698,NasdaqGS,"Jounce Therapeutics, Inc.",USD,479864,512385,1.5499997,0.30815104,5.03 - 14.84,-8.26,-0.5566038,5.03,14.84,1620131400,1620131400,1620131400,-1.146,-2.02,USD,2,-1.39,-4.733813,5.458,5.5034285,1.0765715,0.19561833,8.193189,-1.6131887,-0.19689389,336951264,-3.2574258,1.2055697,15,America/New_York,EDT,-14400000,NMS,0,False,False,6.58,1630526403,0.36000013,6.24,6.6,6.23,317700,"Jounce Therapeutics, Inc.",us_market,PRE,1.12,,,14.84,5.03,5.5,8.19,479.86k,512.38k,51.21M,,30.39M,18.27%,71.69%,1.91M,6.61,5.28%,3.72%,1.97M,,,,,,0.00%,,,,,"Dec 30, 2020","Mar 30, 2021",-68.78%,-69.69%,-11.40%,-20.34%,63.88M,1.66,,25.35M,-41.27M,-43.93M,-1.15,,257.48M,5.03,16.15M,5.78,20.66,5.46,-37.79M,-20.7M,Value,02139,Healthcare,128,6,3,"Jounce Therapeutics, Inc., a clinical-stage immunotherapy company, develops therapies for the treatment of cancer. The company develops vopratelimab, a clinical-stage monoclonal antibody, which is in Phase II clinical trial that binds to and activates the Inducible T cell CO-Stimulator, a protein on the surface of T cells found in various solid tumors. It is also developing JTX-4014, an anti-PD-1 antibody for combination therapy; JTX-8064, an antibody that binds to leukocyte immunoglobulin like receptor B2, which is a cell surface receptor expressed on macrophages; and JTX-1811, an anti-CCR8 monoclonal antibody designed to selectively deplete intra-tumoral T regulatory cells in the tumor microenvironment. Jounce Therapeutics, Inc. was incorporated in 2012 and is headquartered in Cambridge, Massachusetts.",Cambridge,857 259 3840,MA,8,1609372800,1622505600,7,United States,http://jouncetx.com,86400,7,780 Memorial Drive,888 459 2940,Biotechnology
t-3,JNCE,127269000.0,51208400,9013000,,-27964000,,-27968000,7226000,-21023000,-28249000,-28249000,,,,,,4000,0,28249000,21023000,285000,,-27968000,-27968000,288672000.0,31632000.0,127269000.0,53000.0,158901000.0,34000.0,-161570000.0,133000.0,2428000.0,74463000.0,16336000.0,133000.0,25162000.0,131311000.0,,52742000.0,3034000.0,100000.0,20841000,-666000,20841000,61000,3738000,61000,-528000,-21430000,857000,2609000,-5000,114975000.0,en-US,US,EQUITY,True,Delayed Quote,5.7877836,6.23 - 6.6,6.22,0.0,0.0,18,8,finmb_228489698,NasdaqGS,"Jounce Therapeutics, Inc.",USD,479864,512385,1.5499997,0.30815104,5.03 - 14.84,-8.26,-0.5566038,5.03,14.84,1620131400,1620131400,1620131400,-1.146,-2.02,USD,2,-1.39,-4.733813,5.458,5.5034285,1.0765715,0.19561833,8.193189,-1.6131887,-0.19689389,336951264,-3.2574258,1.2055697,15,America/New_York,EDT,-14400000,NMS,0,False,False,6.58,1630526403,0.36000013,6.24,6.6,6.23,317700,"Jounce Therapeutics, Inc.",us_market,PRE,1.12,,,14.84,5.03,5.5,8.19,479.86k,512.38k,51.21M,,30.39M,18.27%,71.69%,1.91M,6.61,5.28%,3.72%,1.97M,,,,,,0.00%,,,,,"Dec 30, 2020","Mar 30, 2021",-68.78%,-69.69%,-11.40%,-20.34%,63.88M,1.66,,25.35M,-41.27M,-43.93M,-1.15,,257.48M,5.03,16.15M,5.78,20.66,5.46,-37.79M,-20.7M,Value,02139,Healthcare,128,6,3,"Jounce Therapeutics, Inc., a clinical-stage immunotherapy company, develops therapies for the treatment of cancer. The company develops vopratelimab, a clinical-stage monoclonal antibody, which is in Phase II clinical trial that binds to and activates the Inducible T cell CO-Stimulator, a protein on the surface of T cells found in various solid tumors. It is also developing JTX-4014, an anti-PD-1 antibody for combination therapy; JTX-8064, an antibody that binds to leukocyte immunoglobulin like receptor B2, which is a cell surface receptor expressed on macrophages; and JTX-1811, an anti-CCR8 monoclonal antibody designed to selectively deplete intra-tumoral T regulatory cells in the tumor microenvironment. Jounce Therapeutics, Inc. was incorporated in 2012 and is headquartered in Cambridge, Massachusetts.",Cambridge,857 259 3840,MA,8,1609372800,1622505600,7,United States,http://jouncetx.com,86400,7,780 Memorial Drive,888 459 2940,Biotechnology
